首页 | 本学科首页   官方微博 | 高级检索  
     

复方黄柏液辅助治疗糖尿病足溃疡的临床疗效分析
引用本文:侯小丽,徐俊,王鹏华,丁敏,王美君,冯书红,姚卫杰,周莹,赵紫熙. 复方黄柏液辅助治疗糖尿病足溃疡的临床疗效分析[J]. 中国实验方剂学杂志, 2016, 22(4): 159-163
作者姓名:侯小丽  徐俊  王鹏华  丁敏  王美君  冯书红  姚卫杰  周莹  赵紫熙
作者单位:天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070,天津医科大学 代谢病医院, 内分泌研究所, 卫生部激素与发育重点实验室, 天津 300070
基金项目:中华中医药学会基金项目(CACMRE2014-B-02)
摘    要:目的:探讨复方黄柏液治疗糖尿病足溃疡的临床疗效。方法:选择2014年3月—2015年4月间天津医科大学代谢病医院足科确诊的糖尿病足溃疡住院患者252例,随机分为试验组和对照组,各126例,两组患者均采用标准化创面处理,试验组在此基础上局部应用复方黄柏液冲洗及浸润,对照组用生理盐水冲洗。治疗8周后,对两组患者溃疡面积,炎症相关指标,临床总有效率,不良事件发生情况进行统计学分析。结果:240例患者完成了该试验(每组各120例),治疗8周后试验组患者在缩小溃疡面积,降低炎症相关指标(白细胞,中性粒细胞百分比,血沉,C反应蛋白)及临床总有效率方面均优于对照组(P0.05),两组患者治疗期间不良事件发生率无统计学差异,试验组内缺血与非缺血患者相比,在缩小溃疡面积,降低炎症指标方面均无统计学差异。结论:复方黄柏液对溃疡创面愈合有明显疗效,对缺血或非缺血性溃疡患者均适用,是辅助治疗糖尿病足溃疡有效、安全的药物。

关 键 词:糖尿病足溃疡  复方黄柏液  辅助治疗  临床疗效
收稿时间:2015-11-10

Analysis on Clinical Efficacy of Compound Huangbai Fluid as Adjunctive Treatment for Diabetic Foot Ulcer
HOU Xiao-li,XU Jun,WANG Peng-hu,DING Min,WANG Mei-jun,FENG Shu-hong,YAO Wei-jie,ZHOU Ying and ZHAO Zi-xi. Analysis on Clinical Efficacy of Compound Huangbai Fluid as Adjunctive Treatment for Diabetic Foot Ulcer[J]. China Journal of Experimental Traditional Medical Formulae, 2016, 22(4): 159-163
Authors:HOU Xiao-li  XU Jun  WANG Peng-hu  DING Min  WANG Mei-jun  FENG Shu-hong  YAO Wei-jie  ZHOU Ying  ZHAO Zi-xi
Affiliation:Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China,Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China and Key Lab of Hormones and Development (Ministry of Health), Research Institute of Endocrinology, Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, China
Abstract:Objective: To explore the clinical efficacy of compound Huangbai fluid for the treatment of diabetic foot ulcer (DFU). Method: The 252 patients with DFU were recruited from the Metabolic Diseases Hospital of Tianjin Medical University between March 2014 and April 2015. They were randomly divided into the experimental group (EG, n = 126) and control group (CG, n=126). The standardized wound treatment was used in both groups, however, the ulcer wounds in the EG were also rinsed and infiltrated with compound Huangbai fluid, while in the CG, normal saline was used for rinsing. After treatment for 8 weeks, the ulcer size, inflammation related indicators, total clinical efficiency and incidence of adverse events were compared with statistical analysis between two groups. Result: The 240 subjects completed this study (n=120 in each group). After treatment for 8 weeks, the EG was superior to CG in term of the reduction of ulcer size,reduction of inflammation related indicators(white blood cell, neutrophil, C-reactive protein, erythrocyte sedimentation rate), and total clinical efficacy (P< 0.05). No significant differences in adverse events were found between two groups. There were no statistical differences in the reduction of ulcer size and inflammation related indicators were observed between ischemic and non-ischemic patients in EG. Conclusion: Compound Huangbai fluid has obvious clinical efficacy on ulcer wound healing and it is applicable to both ischemic and non-ischemic ulcer patients, so it is an effective and safe drug as an adjunctive treatment of DFU.
Keywords:diabetic foot ulcer  compound Huangbai fluid  adjunctive treatment  clinical efficacy
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号